Tenon Medical, Inc.

As of June 30, 2026, Tenon Medical, Inc. carries a market capitalization of 5.67M, placing it among publicly traded companies globally. Its enterprise value stands at 12.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tenon Medical, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Tenon Medical, Inc. has 496,456.00 shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.63, and the price-to-book ratio stands at -1.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.74M versus a market cap of 5.67M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tenon Medical, Inc. maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -325.76, indicating conservative leverage, while an interest coverage ratio of -11.97 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -130.22, reflecting losses generated across the asset base. The company generates approximately 202,361.90 in revenue per employee across its workforce of 26.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.40 indicates how many times Tenon Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Tenon Medical, Inc.'s stock has declined approximately 94.63% over the past 52 weeks. The 50-day moving average sits at 4.14, while the 200-day moving average is 17.89.

Over the twelve months ended June 30, 2026, Tenon Medical, Inc. generated 5.31M in revenue and converted that into -13.70M in net income, yielding earnings per share of -47.04. EBITDA reached -12.30M, while operating income came in at -12.89M.

As of June 30, 2026, Tenon Medical, Inc. holds 1.68M in cash and equivalents against 5.68M in total debt, resulting in a net debt position of 2.66M. Total book value stands at -4.82M, with working capital of -3.50M providing operational flexibility.

Tenon Medical, Inc. produced -11.77M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -309,000.00 in capital expenditures, free cash flow totaled -12.07M - equivalent to -41.47 per share.

Over the twelve months ended June 30, 2026, Tenon Medical, Inc. posted a gross margin of 66.81, reflecting its pricing power and cost economics. The operating margin of -242.70 and net profit margin of -257.85 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -363.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -117.39, meaning Tenon Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Tenon Medical, Inc.'s most recent stock split took place on August 10, 2026 with a 35:1 split ratio.

As of June 30, 2026, Tenon Medical, Inc. has an Altman Z-Score of -23.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.